Inherited Liver Diseases

• Audio chapter
  Single-voice audio, listen on the commute.
• ABIM-format MCQs
  5-option vignettes with full wrong-answer teaching.
• Study guide
  Tables, decision trees, primary sources.
• AI tutor
  Chapter-grounded, answers the question you're stuck on.

What this chapter covers

• Section 22.1: Hereditary hemochromatosis iron metabolism, genetics, and penetrance

  Hereditary hemochromatosis iron overload is driven by inappropriately low hepcidin signaling, which removes the brake on enterocyte ferroportin and accelerates dietary iron absorption.

• Section 22.2: HH diagnosis, phlebotomy, and HCC surveillance

  Diagnosis (ACG 2019, with EASL 2022 endorsing the same approach) requires fasting transferrin saturation at least 45 percent in men or 40 percent in women plus elevated ferritin (over 300 ng per mL in men or 200 ng per mL in women); HFE genotyping confirms C282Y homozygosity.

• Section 22.3: Wilson disease diagnosis and Leipzig score

  Wilson disease (ATP7B on chromosome 13q14.3, with over 500 mutations described and approximately 380 disease-associated; H1069Q is the most common variant in European descent at 15 to 25 percent prevalence) impairs biliary copper excretion and ceruloplasmin loading.

• Section 22.4: Wilson treatment, pregnancy, and monitoring

  First-line chelation in symptomatic Wilson is trientine, paired with zinc for maintenance and counseling on a low-copper diet (avoid shellfish, organ meats, nuts, chocolate, mushrooms).

• Section 22.5: Alpha-1 antitrypsin deficiency

  PiZZ alpha-1 antitrypsin deficiency causes both pulmonary disease (early-onset panacinar emphysema, lower-lobe predominant in non-smokers) and hepatic disease (chronic hepatitis to cirrhosis).

• Section 22.6: Cystic fibrosis-associated liver disease

  Cystic fibrosis affects approximately 1 in 3,000 live births in the United States and Northern Europe, and CF-associated liver disease (CFLD) develops in 5 to 10 percent of CF patients over time.

• Section 22.7: Polycystic liver disease

  Polycystic liver disease in the autosomal dominant polycystic kidney disease (ADPKD) context accompanies kidney cysts; ADPKD is autosomal dominant with PKD1 mutations in about 85 percent and PKD2 mutations in the remainder, producing renal and hepatic cyst growth driven by abnormal cholangiocyte proliferation and fluid secretion through dysregulated planar cell polarity signaling.

• Section 22.8: PFIC, BRIC, and Alagille syndrome

  The familial cholestatic syndromes split by GGT pattern and by progression.

Podcast episodes

1. 01

   Inherited Liver Diseases: Hereditary Iron Overload

   Hemochromatosis is a low hepcidin letting ferroportin release iron unchecked, and every decision in the episode follows from that. The episode starts with the two results that make the diagnosis, a raised fasting transferrin saturation and ferritin, then HFE genotyping. It covers which genotypes load iron, what incomplete penetrance means for relatives, and how to recognize secondary hyperferritinemia and the non-HFE forms. It then turns to staging the liver, phlebotomy induction and maintenance, habits to change, what reverses and what does not, lifelong cancer surveillance in cirrhosis, transplant, and testing of siblings and the spouse.

   Read the transcript →
2. 02

   Inherited Liver Diseases: Wilson Disease

   Wilson disease is a failed copper pump, and nearly every decision in this episode follows from that. ATP7B failure blocks biliary copper excretion and leaves ceruloplasmin low, so the episode starts with whom to suspect, from about age three to forty-five, including lean patients labeled with MASLD. It then builds the diagnosis with the Leipzig score, shows why ceruloplasmin cannot decide alone, and moves to ATP7B testing and sibling screening. Treatment follows: trientine first, the pitfalls of iron, zinc, and penicillamine, zinc for maintenance, and urine copper targets read with free copper. It closes with pregnancy and contraception, and with transplant for fulminant or decompensated disease.

   Read the transcript →
3. 03

   Inherited Liver Diseases: Four More Diseases

   This final episode of the chapter treats each inherited liver disease as a question of mechanism, and the mechanism drives the test and the treatment. Alpha-one antitrypsin deficiency injures the lung through lost protein and the liver through trapped protein, so the serum level misleads and augmentation helps only the lung. Cystic fibrosis causes patchy biliary cirrhosis, so biopsy misleads, portal hypertension can precede liver failure, and the modulator must match the mutation. Polycystic liver disease is treated by symptoms, starting with a somatostatin analog before surgery. Childhood cholestatic syndromes are sorted by GGT and by extrahepatic findings.

   Read the transcript →

Key topics

• ·Hepcidin, ferroportin, and iron absorption
• ·C282Y and H63D genotypes
• ·Ancestry and carrier frequency
• ·Diagnostic thresholds and HFE testing
• ·Incomplete penetrance and monitoring
• ·Secondary hyperferritinemia
• ·Non-HFE hemochromatosis types
• ·Biopsy iron patterns
• ·Staging, phlebotomy, and diet
• ·Reversibility, cancer surveillance, and family screening
• ·ATP7B copper pump and who to suspect
• ·Liver and neuropsychiatric presentations
• ·Leipzig score diagnosis
• ·Ceruloplasmin limits and hepatic copper
• ·ATP7B testing and sibling screening
• ·Trientine versus penicillamine
• ·Zinc for maintenance
• ·Urine copper and free copper monitoring
• ·Pregnancy and contraception
• ·Liver transplant indications
• ·Alpha-one antitrypsin deficiency mechanisms
• ·Pi phenotypes and liver risk
• ·Diagnosis and treatment of PiZZ disease
• ·Cystic fibrosis liver disease
• ·Cystic fibrosis modulators by mutation
• ·Genetic forms of polycystic liver disease
• ·Symptom-based treatment of polycystic liver
• ·ARPKD and congenital hepatic fibrosis
• ·PFIC, BRIC, and GGT
• ·Alagille syndrome